Group 1 - The first nickel-free high-nitrogen rapamycin drug-eluting coronary stent system has been approved for market release in China, marking a significant breakthrough in high-end medical devices [1][2] - The new stent system offers a "zero nickel toxicity" design, providing a safer option for the 200 million patients suffering from coronary heart disease globally [1][2] - The development of this new material took 25 years, involving collaboration among top institutions in China, showcasing the country's ability to tackle major scientific challenges [2][3] Group 2 - The new stent's mechanical strength and biocompatibility surpass international counterparts, making it a unique choice for patients with nickel allergies [3] - The clinical trial results indicate a significant advantage, with a 9-month restenosis rate of only 0.4% compared to 3.0% in the control group [3] - The successful development of the nickel-free high-nitrogen stent positions China as a leader in the global coronary stent market, moving from imitation to innovation [3][5] Group 3 - The nickel-free high-nitrogen stent has generated substantial domestic and international orders, indicating a strong market demand [5] - The application of nickel-free high-nitrogen medical alloys extends beyond cardiology, showing potential in orthopedics, dentistry, and neurosurgery [5] - This innovation is a representative achievement of China's new materials strategy and contributes significantly to the global healthcare industry [6]